ArticlePDF Available

Inappropriate Intra‐cervical Injection of Radiotracer for Sentinel Lymph Node Mapping in a Uterine Cervix Cancer Patient: Importance of Lymphoscintigraphy and Blue Dye Injection

Authors:

Abstract

Herein, we report a case of sentinel lymph node mapping in a uterine cervix cancer patient, referring to the nuclear medicine department of our institute. Lymphoscintigraphy images showed inappropriate intra‐cervical injection of radiotracer. Blue dye technique was applied for sentinel lymph node mapping, using intra‐cervical injection of methylene blue. Two blue/cold sentinel lymph nodes, with no pathological involvement, were intra‐operatively identified, and the patient was spared pelvic lymph node dissection. The present case underscores the importance of lymphoscintigraphy imaging in sentinel lymph node mapping and demonstrates the added value of blue dye injection in selected patients. It is suggested that preoperative lymphoscintigraphy imaging be considered as an integral part of sentinel lymph node mapping in surgical oncology. Detailed results of lymphoscintigraphy images should be provided for surgeons prior to surgery, and in case the sentinel lymph nodes are not visualized, use of blue dye for sentinel node mapping should be encouraged.
* Corresponding author: Ramin Sadeghi, Nuclear Medicine Research Center, Mashhad University of Medical
Sciences, Mashhad, Iran. Tel: +985118012202; Fax: +985118933186; Email: sadeghir@mums.ac.ir;
raminsadeghi1355@yahoo.com
© 2014 mums.ac.ir All rights reserved.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
InappropriateIntracervicalInjectionofRadiotracerfor
SentinelLymphNodeMappinginaUterineCervixCancer
Patient:ImportanceofLymphoscintigraphyandBlueDye
Injection
SimaKadkhodayan1,ElhamHosseiniFarahabadi1,ZohrehYousefi1,Malihe
Hasanzadeh1,RaminSadeghi2*
1 Women’sHealthResearchCenter,MashhadUniversityofMedicalSciences,Mashhad,Iran
2 NuclearMedicineResearchCenter,MashhadUniversityofMedicalSciences,Mashhad,Iran
ARTICLEINFOABSTRACT
Articletype:
Casereport
Herein,wereportacaseofsentinellymphnodemappinginauterine cervix cancer
patient, referring to the nuclear medicine department of our institute.
Lymphoscintigraphy images showed inappropriate intra‐cervical injection of
radiotracer.Bluedye techniquewasapplied for sentinellymph node mapping,using
intra‐cervicalinjectionof methyleneblue. Two blue/coldsentinel lymphnodes,with
no pathological involvement, were intra‐operatively identified,andthepatientwas
sparedpelviclymphnodedissection.Thepresentcaseunderscorestheimportanceof
lymphoscintigraphy imaging in sentinel lymph node mapping and demonstrates the
added value of blue dye injection in selected patients. It is suggested that pre‐
operative lymphoscintigraphy imaging be considered as an integral part of sentinel
lymph node mapping in surgical oncology. Detailed results of lymphoscintigraphy
imagesshouldbeprovidedforsurgeonspriortosurgery,andin case the sentinel
lymphnodes arenot visualized,use ofblue dyefor sentinelnodemappingshouldbe
encouraged.
Articlehistory:
Received:7Mar2014
Revised:2Apr2014
Accepted:15May2014
Keywords:
99mTc‐Phytate
Cervicalcancer
Lymphoscintigraphy
Methyleneblue
Sentinelnode
Pleasecitethispaperas:
Kadkhodayan S, Hosseini FarahabadiE,YousefiZ,HasanzadehM,Sadeghi R. Inappropriate Intra‐cervical Injection of
RadiotracerforSentinelLymphNode Mappingin aUterineCervix CancerPatient: Importanceof Lymphoscintigraphy
andBlueDyeInjection.AsiaOceaniaJNuclMedBiol.2014;2(2):
Introduction
Sentinelnodemapping,asausefulmethod
for regional lymph node staging, minimizes the
morbidity associated with lymph node
dissectioninpatientswithsolidtumors.
Theconceptof sentinelnodemapping relies
on an orderly and predictable pattern of
lymphaticflowfromtumors.Sentinelnodesare
thefirstlymphnodesin thelymphaticdrainage
system of tumors, and can be considered as
surrogates for regional lymph nodes, regarding
thepathologicalinvolvement(1,2).
Two conventional methods for sentinel
lymphnodemappingareinjectionofradiotracer
andbluedye. Acombinationof radiotracerand
bluedyeinjectionforlymphaticmappingis
found to increase the detection rate and
decreasethefalse‐negativerateofsentinelnode
biopsy(3).However,severalauthorshave
proposedamorerestricteduseofbluedye
injection due to potential life‐threatening
complications, associated with this method (4‐
6).
Casereport
A 56‐year‐old female patient with a
histologically proven squamous cell carcinoma
(2 cm in diameter) of uterine cervix was
scheduled for sentinel node mapping in the
K
adkhoda
y
Page Num
b
Figure1.
E
the patien
t
(bluelarg
e
Figure2.
imagesof
t
theinjecti
o
nuclear
The pa
t
hystere
c
oophor
e
Eigh
t
patient
r
99mTc‐
P
mCi
/
Lympho
posterio
min af
t
variable
as previ
was eq
u
collimat
o
photope
thehue
o
Lym
p
improp
e
as most
vagina (
seenon
t
y
an S et al
b
e
r
E
arlylymphosci
t
’s hue in the l
o
e
arrows).Nose
n
Delayed anter
t
hepatient.No
s
o
nsitesinthec
e
medicine d
e
t
ient was
p
c
tomy an
d
e
ctomy.
t
een hours
r
eceived tw
o
P
hytate at 3
/
0.1 cc
scintigraphy
r and later
a
t
er the inj
e
anglegam
m
ously specifi
u
ipped with
o
r and ima
g
akandscatt
e
o
fthepatien
t
p
hoscintigra
p
e
r injection
o
oftheradi
o
Figure1);a
l
t
helymphos
c
ntigraphyimag
e
o
wer row. Note
n
tinelnodecoul
ior/posterior l
y
s
entinelnodeis
e
rvix
e
partment o
f
p
lanned to
d
bilater
a
before the
o
 intra‐cervi
c
and 9 o’clo
c
for eac
h
images
w
a
l views we
r
e
ction, usin
g
m
acamera(E
C
ed (7). The
g
low‐energy
h
g
es were t
a
e
rphotopea
k
t
)(1image/
5
p
hy ima
g
o
f radiotrace
r
o
activity wa
s
l
so, no senti
n
c
intigraphyi
m
e
softhepatient
.
minimal activit
y
dbevisualized
i
y
mphoscintigra
p
visible.Arrows
f
ourinstit
u
undergo to
a
l salpin
g
surgery,
t
c
alinjections
c
k positions
h
injectio
n
w
ith anteri
o
r
e obtained
g
adualh
e
C
AM,Sieme
n
g
amma cam
e
h
igh‐resoluti
a
ken by 99
m
k
s(forimagi
5
min).
g
es sho
w
r
inthecer
v
s
 visible in
t
n
el nodes w
e
m
ages.
.
Theoriginali
m
y
 in the cervix
(
i
nthepelvis
p
hy
are
u
te.
tal
g
o‐
t
he
of
(1
n
).
o
r‐
30
e
ad
n
s),
e
ra
on
m
Tc
ng
w
ed
v
ix,
t
he
e
re
r
a
l
y
s
a
l
y
t
w
(
0
p
e
F
r
i
n
r
e
d
e
e
x
f
o
l
y
D
s
e
b
y
b
e
n
e
i
n
s
e
w
a
n
s
o
u
s
I
n
t
h
b
r
e
x
m
agesareshow
n
(
black arrows)
a
The patie
n
a
diotracer
y
mphoscintig
a
me finding
y
mph nodes
w
o intra‐cer
v
0
.5 cc/inject
i
e
rformedus
i
r
ance)andb
l
Two blu
e
n
tra‐operativ
e
e
gions. How
e
e
tected by t
h
x
amination
o
o
r pathologi
c
y
mphnoded
i
D
iscussion
The impo
r
e
ntinel node
y
manyre
s
e
hind blue d
e
gative rate
n
crease the
e
ntinelnode
s
However,
a
w
ith some
n
aphylactic
o
me authors
s
e of blue d
y
n
animport
a
h
atthemarg
i
r
east canc
e
x
perience of
L
ymphosci
n
A
sia Oceania
n
intheupperro
a
nd extension
o
n
t refused to
injectio
n
raphy imag
e
s without
(Figure 2).
v
ical injectio
n
i
on), and ly
m
i
ngagamm
a
l
uedyetech
n
e
sentineln
o
e
ly in the ri
g
e
ver, no hot
h
e gamma
p
o
fthesentin
e
c
al involve
m
i
ssectionwa
s
r
tance of bl
u
mapping h
a
s
earchers (
5
ye techniqu
e
of sentinel
intraope
r
s
.
a
ddition of
b
risks inclu
d
reactions (
6
have propo
s
y
e in sentine
a
nt study, D
e
i
nalbenefito
e
r patients
surgeons in
c
n
tigraphy in Cer
v
J Nucl Med Bio
l
.
wandthescatt
e
o
f radiotracer i
n
undergo an
n
. Pre‐
o
e
s also sh
o
any visible
The patient
n
s of methy
l
m
phatic map
p
a
probe(EU
R
n
ique.
o
des were
i
g
htandleft
o
sentinel no
d
p
robe. Froze
n
e
lnodeswas
m
ent, and
n
s
performed.
u
e dye tec
h
a
s been dem
o
5
, 8). The
e
istodecre
a
 node map
p
r
ative dete
c
b
lue dye is a
d
ing life‐th
r
6
, 9, 10).
T
s
ed a more
r
l node map
p
e
rossis et al.
fbluedyein
j
decreases
c
reases (12)
.
v
ical Cance
r
2014; 2(2):
e
rogramsof
n
thevagina
y further
o
perative
o
wed the
sentinel
received
l
ene blue
p
ing was
R
OPROBE,
i
dentified
o
bturator
d
es were
n
section
negative
n
o pelvic
h
nique in
o
nstrated
rationale
a
se false‐
p
ing and
c
tion of
ssociated
r
eatening
T
herefore,
r
estricted
p
ing (11).
reported
j
ectionin
as the
.
Another
Lymphoscintigraphy in Cervical Cancer Kadkhodayan S et al
Asia Oceania J Nucl Med Biol. 2014; 2(2): Page Number
studybySadeghietal.reportedsimilarfindings,
and showed the marginal benefits of blue dye
technique in case of sentinel node visualization
onlymphoscintigraphyimages(4).
The present case shows the importance of
lymphoscintigraphy imaging as an integral part
of sentinel node mapping. Lymphoscintigraphy
imagesindicatedtheinappropriateinjectionof
radiotracer(inour case,failureto injecttheair
bubblebehindtheradiotracerinsyringes),and
the surgeon was informed about the results
beforethesurgery.Bluedyetechniquewas
successful for lymphatic mapping and the
patient was spared pelvic lymph node
dissection.
Therefore, non‐visualization of sentinel
nodesonlymphoscintigraphy imagesshouldbe
reportedtosurgicaloncologists,anduseofblue
dye technique should be promoted in similar
clinicalsituations.
References
1. TarjanM.Sentinellymphnodebiopsyin
Hungary. Results with a revolutionary new
method in surgical oncology. Magy Onkol.
2002;46(4):315‐21.
2. Ellis LM. A perspective on sentinel lymph node
biopsyincolorectalcancer:theracebetween
surgicaltechnologyandmolecularoncology.Ann
SurgOncol.2000;7(7):475‐6.
3. SnojM, GolouhR, Movrin‐StanovnikT,Vidergar‐
KraljB. Addedvalueof bluedyeinsentinelnode
biopsyforbreastcancer.JExpClinCancerRes.
2003;22(4):551‐5.
4. Sadeghi R, Alesheikh G, Zakavi SR, Fattahi A,
AbdollahiA,AssadiM,etal.Added valueof blue
dye injection in sentinel node biopsy of breast
cancer patients: Do all patients need blue dye?.
IntJSurg.2014;12(4):325‐8.
5. Ramin S, Azar FP, Malihe H. Methylene blue as
thesafestbluedyeforsentinelnodemapping:
emphasis on anaphylaxis reaction. Acta Oncol.
2011;50(5):729‐31.
6. Jangjoo A, Forghani MN, Mehrabibahar M,
SadeghiR.Anaphylaxisreactionofabreast
cancer patient to methylene blue during breast
surgerywith sentinelnode mapping.Acta Oncol.
2010;49(6):877‐8.
7. MomennezhadM,ZakaviSR,DabbaghKakhkiVR,
Jangjoo A, Ghavamnasiri MR, Sadeghi R.
Scatterogram: a method for outlining the body
during lymphoscintigraphy without using
externalflood source.RadiolOncol.2011;45(3):
184‐8.
8. Kang T, Yi M, Hunt KK, Mittendorf EA, Babiera
GV, Kuerer H, et al. Does blue dye contribute to
successofsentinelnodemappingforbreast
cancer?.AnnSurgOncol.2010;17:280‐5.
9. DangY,EngelJ.Patentbluedyeandanatypical
anaphylactic reaction after sentinel lymph node
biopsy in early breast cancer. Breast J. 2012;18
(1):91‐2.
10. Noirot A, Vigneau A, Salengro A, Bonnet F.
Allergicreactiontopatentbluedyeforsentinel
lymph node detection during uterus oncological
surgery. Ann Fr Anesth Reanim. 2005;24 (5):
541‐2.
11. JangjooA,ShabaniG,ZakaviR,KakhkiVRD,
Sadeghi R. Disappearanceofasentinelnodeon
the delayed lymphoscintigraphy imaging of a
breast cancer patient: Importance of blue dye
injection.Nowotwory.2011;61(1):30‐1.
12. DerossisAM,Fey J,YeungH, YehSD, Heerdt AS,
PetrekJ,etal.Atrendanalysisoftherelative
value of blue dye and isotope localization in
2,000 consecutive cases of sentinel node biopsy
for breast cancer. J Am Coll Surg. 2001;193 (5):
473‐8.
... Therefore, more studies with larger sample sizes are warranted to confirm the results of these studies. In agreement with several previous studies [26][27][28], the radiation safety of ovarian SLN mapping was also reiterated in our study. ...
Article
Full-text available
Purpose Ovarian cancer in the early stage requires a complete surgical staging, including radical lymphadenectomy, implying subsequent risk of morbidity and complications. Sentinel lymph node (SLN) mapping is a procedure that attempts to reduce radical lymphadenectomy-related complications and morbidities. Our study evaluates the feasibility of SLN mapping in patients with ovarian tumors by the use of intraoperative Technetium-99m-Phytate (Tc-99m-Phytate) and postoperative lymphoscintigraphy using tomographic (single-photon emission computed tomography/computed tomography (SPECT/CT)) acquisition. Materials and Methods Thirty-two patients with ovarian mass participated in this study. Intraoperative injection of the radiopharmaceutical was performed just after laparotomy and before the removal of tumor in utero-ovarian and suspensory ligaments of the ovary just beneath the peritoneum. Subsequently, pelvic and para-aortic lymphadenectomy was performed for malignant masses, and the presence of tumor in the lymph nodes was assessed through histopathological examination. Conversely, lymphadenectomy was not performed in patients with benign lesions or borderline ovarian tumors. Lymphoscintigraphy was performed within 24 hr using tomographic acquisition (SPECT/CT) of the abdomen and pelvis. Results Final pathological examination showed 19 patients with benign pathology, 5 with borderline tumors, and 6 with malignant ovarian tumors. SPECT/CT identified SLNs in para-aortic-only areas in 6 (20%), pelvic/para-aortic areas in 14 (47%), and pelvic-only areas in 7 (23%) cases. Notably, additional unusual SLN locations were revealed in perirenal, intergluteal, and posterior to psoas muscle regions in three patients. We were not able to calculate the false negative rate due to the absence of patients with involved lymph nodes. Conclusion SLN mapping using intraoperative injection of radiotracers is safe and feasible. Larger studies with more malignant cases are needed to better evaluate the sensitivity of this method for lymphatic staging of ovarian malignancies.
... Sentinel node detection failure is usually due to lymphatic basin tumor involvement which impedes the radiotracer movement in the lymphatic system [5,17]. However, possibility of technical errors should always born in mind in case of sentinel node non-visualization [14,16,18]. In our case, High uptake of the radiotracer in the liver and low injection site count (as faint star artifact), rose the suspicion of possible inadvertent intravascular injection of the radiotracer. ...
Article
Full-text available
We reported a 35 year old breast cancer patient who was referred to our nuclear medicine department for sentinel node mapping. She was planned to undergo mastectomy and lymphatic mapping. A dose of Tc-99m Phytate was injection in the peri-areolar region in an intra-dermal fashion. Two hours post-injection no sentinel node was visible in the axilla. Due to a high liver uptake, inadvertent intra-vascular injection was suspected and another dose of the radiotracer was injected in the breast. Lymphoscintigraphy two minutes post-injection showed an axillary sentinel node. Our case underscores the importance of second radiotracer injection in case of sentinel node non-visualization.
... The radiation safety of sentinel node mapping has been addressed before in several studies [41]. Radiation dose to the patients is very low as systemic absorption of the tracer is minimal and the injection site is removed from the body during surgery [42]. Radiation to the surgical and nuclear medicine staff as well as the pathologists is also well below the ICRP threshold limit [43]. ...
Article
Full-text available
Background Experience on sentinel node mapping in ovarian tumors is very limited. We evaluated the sentinel node concept in ovarian tumors using intra-operativeTc-99m-Phytate injection and lymphoscintigraphy imaging. Methods Thirty-five patients with a pelvic mass due to an ovarian pathology were included in the study. The radiotracer was injected just after laparotomy and before removal of the tumor either beneath the normal cortex (10 patients) or in the utero-ovarian and suspensory ligaments of the ovary just beneath the peritoneum two injections of the radiotracer (25 patients). For malignant masses, the sentinel nodes were identified using a hand held gamma probe. Then standard pelvic and para-aortic lymphadenectomy was performed. In case of benign pathologies or borderline ovarian tumors on frozen section, lymphadenectomy was not performed. The morning after surgery, all patients were sent for lymphoscintigraphy imaging of the abdomen and pelvis. Results Sentinel node was identified only in 4 patients of the cortical injection group. At least one sentinel node could be identified in 21 patients of the sub-peritoneal group. Sentinel nodes were identified only in the para-aortic area in 21, pelvic/para-aortic areas in 2, and pelvic only area in 2 patients. Three patients had lymph node involvement and all had involved sentinel nodes (no false negative case). Conclusion Sentinel node mapping using intra-operative injection of the radiotracer (in the utero-ovarian and suspensory ligaments of the ovary just beneath the peritoneum) is feasible in ovarian tumors. Technical aspects of this method should be explored in larger multicenter studies in the future.
... In this case, intra-operative blue dye injection should be encouraged in order to enhance the chance of intraoperative sentinel node detection. 111 The clinical value of lymphoscintigraphy has increased since the advent of the hybrid tomographic technique SPECT/CT. Belhocine et al., in 2013 reported that SPECT/CT lymphoscintigraphic images may have a direct impact on the treatment planning of patients with uterine cervical cancer. ...
Article
We reviewed the available literature on the accuracy of sentinel node mapping in the lymph nodal staging of uterine cervical cancers. MEDLINE and Scopus were searched by using "sentinel AND (cervix OR cervical)" as key words. Studies evaluating the accuracy of sentinel node mapping in the lymph nodal staging of uterine cervical cancers were included if enough data could be extracted for calculation of detection rate and/or sensitivity. Sixty-seven studies were included in the systematic review. Pooled detection rate was 89.2% [95% CI: 86.3-91.6]. Pooled sensitivity was 90% [95% CI: 88-92]. Sentinel node detection rate and sensitivity were related to mapping method (blue dye, radiotracer, or both) and history of pre-operative neoadjuvant chemotherapy. Sensitivity was higher in patients with bilaterally detected pelvic sentinel nodes compared to those with unilateral sentinel nodes. Lymphatic mapping could identify sentinel nodes outside the routine lymphadenectomy limits. Sentinel node mapping is an accurate method for the assessment of lymph nodal involvement in uterine cervical cancers. Selection of a population with small tumor size and lower stage will ensure the lowest false negative rate. Lymphatic mapping can also detect sentinel nodes outside of routine lymphadenectomy areas providing additional histological information which can improve the staging. Further studies are needed to explore the impact of sentinel node mapping in fertility sparing surgery and in patients with history of neoadjuvant chemotherapy. Copyright © 2014 Elsevier Ltd. All rights reserved.
Chapter
The concept of sentinel node (SN) is an important aspect of surgical oncology that has revolutionized the treatment of solid tumors. The concept of sentinel node mapping suggests that lymphatic basin involvement starts from the sentinel nodes, and if sentinel nodes are pathologically clear from tumor cells, the other lymph nodes of the basin are clear either. In the current chapter, general aspects of sentinel node mapping have been discussed, including various mapping materials and radiopharmaceuticals; injection site, time, dose, and volume; imaging (lymphoscintigraphy); and gamma-probe-related issues. Special considerations for sentinel node mapping in breast cancer, melanoma, and uterine cervix, endometrial, vulvar, penile, colorectal, and head and neck cancers were also discussed.
Article
Full-text available
Sentinel lymph node biopsy with the aid of radiotracer injection is the standard method for axillary lymph node staging in early breast cancer patients. Currently a 2-day protocol (performing surgery the day after the injection of the tracer) is being performed with excellent results. We report the disappearance of a sentinel lymph node on the delayed (24 hour) lymphoscintigraphy imaging of a patient despite its visualization on the early images. The sentinel lymph node was detected during surgery only by the blue dye technique. This case shows the importance of delayed imaging, as well as the importance of using blue dye in a 2-day protocol sentinel node biopsy.
Article
Full-text available
We evaluated the feasibility of outlining the body with scattered photons using a low dose intradermal injection of the radiotracer. PATIENTS AND METHODS.: Sixty breast cancer patients were included into the study. 30 minutes post radiotracer injection static lymphoscintigraphy images were acquired using low energy high resolution collimator in anterior and lateral views. For patients with 2-day protocol another set of images was taken 20 hours post-injection. Two photopeaks were used during imaging: 1-Tc-99m (130-150 keV) and 2- Scatter photons (60-120). The fusion image of these two images was constructed by NM-NM fusion workflow of the workstation. The usual body outline of the patients was also acquired in 20 cases using the external flood source without moving the patients from their positions. The early (30 minute image) scatterograms of the patients clearly showed the contour of the body. The 20 hour scatterograms were not as high quality as the corresponding early images. The constructed overlaid images showed the location of the axillary sentinel nodes and the body contours clearly for early scatterograms but not the delayed (20 hour) ones. The processing of the images for the reconstruction of overlaid scatterograms took the mean time of 10±5 seconds. Imaging the scattered photons is feasible for the intradermal low dose injection of the radiotracers in order to outline the body contour. This imaging method does not increase the radiation exposure of the patients or operators and does not extend the time of imaging either.
Article
In the current study, we evaluated the incremental value of blue dye injection in sentinel node mapping of early breast cancer patients. We specially considered the experience of the surgeons and lymphoscintigraphy results in this regard. 605 patients with early stage breast cancer were retrospectively evaluated in the study. Patients underwent sentinel node mapping using combined radiotracer and blue dye techniques. Lymphoscintiraphy was also performed for 590 patients. Blue dye, radioisotope, and overall success rates in identifying the sentinel lymph node were evaluated in different patient groups. The benefit of blue dye and radioisotope in identifying the sentinel lymph nodes was also evaluated. Marginal benefits of both blue dye and isotope for overall sentinel node detection as well as pathologically involved sentinel nodes were statistically higher in inexperienced surgeons and in patients with sentinel node visualization failure. In the patients with sentinel node visualization on lymphoscintigraphy, 6 sentinel nodes were detected by blue dye only. All these six nodes were harvested by inexperienced surgeons. On the other hand 8 sentinel nodes were detected by dye only in the patients with sentinel node non-visualization. All these nodes were harvested by experienced surgeons. The use of blue dye should be reserved for inexperienced surgeons during their learning phase and for those patients in whom lymphoscintigraphy failed to show any uptake in the axilla.
Article
We sought to evaluate the utilization of blue dye in addition to radioisotope and its relative contribution to sentinel lymph node (SLN) mapping at a high-volume institution. Using a prospectively maintained database, 3,402 breast cancer patients undergoing SLN mapping between 2002 and 2006 were identified. Trends in utilization of blue dye and results of SLN mapping were assessed through retrospective review. Statistical analysis was performed with Student t test and chi-square analysis. 2,049 (60.2%) patients underwent mapping with dual technique, and 1,353 (39.8%) with radioisotope only. Blue dye use decreased gradually over time (69.8% in 2002 to 48.3% in 2006, p < 0.0001). Blue dye was used significantly more frequently in patients with lower axillary counts, higher body mass index (BMI), African-American race, and higher T stage, and in patients not undergoing skin-sparing mastectomy. There was no difference in SLN identification rates between patients who had dual technique versus radiocolloid alone (both 98.4%). Four (0.8%) of 496 patients who had dual mapping and a positive SLN had a blue but not hot node as the only involved SLN. None of these four had significant counts detected in the axilla intraoperatively. Nine (0.4%) of 2,049 patients who had dual mapping had allergic reactions attributed to blue dye. Blue dye use has decreased with increasing institutional experience with SLN mapping. In patients with adequate radioactive counts in the axilla, blue dye is unlikely to improve the success of sentinel node mapping.
Article
Among the advocates of blue dye, isotope, or combined dye-isotope mapping of the sentinel lymph node (SLN) for breast cancer, there is no universal consensus as to which technique is optimal and whether the relative value of each method changes with increasing experience. The objective of this study was to examine the relative contributions of blue dye and radioisotope to successful identification of the SLN as the SLN-mapping technique evolved over our first 2,000 consecutive cases. Using the first 2,000 consecutive SLN biopsy procedures for breast cancer, performed by eight surgeons (none previously experienced in SLN techniques) at one institution, using a combined technique of blue dye and isotope mapping, we report the institutional learning curve and the relative contributions of dye and isotope to identifying both the SLN and the positive SLN, by increments of 500 cases. Comparing the first 500 with the most recent 500 cases, success in identifying the SLN by blue dye did not improve with experience, although success in isotope localization steadily increased, from 86% to 94% (p < 0.00005). With the increasing success of isotope mapping, the marginal benefit of blue dye (the proportion of cases in which the SLN was identified by blue dye alone) steadily declined, from 9% to 3% (p = 0.0001). Parallel to this trend, the proportion of positive SLNs identified by blue dye did not change with experience (89% to 90%), but isotope success steadily increased, from 88% to 98% (p = 0.0015). The proportion of positive SLNs identified by blue dye alone declined from 12% to 2% (p = 0.0015). Using a combined technique of blue dye and radioisotope mapping, and with refinement of the radioisotope technique, we report 97% success identifying the SLN. Although we continue to recommend the use of both methods in SLN mapping for breast cancer, we observe with experience a declining marginal benefit for blue dye.